Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival...
Company Announcement COPENHAGEN, Denmark; October 28, 2026 Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing...
ir.genmab.com